Abstract:Having trained as an endocrinologist and diabetologist, as well as a nephrologist interested in phosphate and glucose transport in the kidney ( 1 ), it was logical to combine the two disciplines. It also made sense to utilize phlorizin, a dual SGLT2/SGLT1 inhibitor, as a therapeutic option for the treatment of type 2 diabetes (T2D) based on the premise that the induction of glucosuria would reduce the plasma glucose concentration (Figure 1). Because reduced glucose levels ameliorate glucotoxicity, lead to reversal of insulin resistance in muscle ( 2 ), and improve β cell function ( 3 ), we set out to test phlorizin using partially (90%) pancreatectomized diabetic rats. SGLT2 inhibitors acutely induce glucosuria, which persists as long as the SGLT2i therapy is continued. Treatment with SGLT2 inhibitors, such as phlorizin, promotes glucosuria and leads to a decline in fasting plasma glucose concentration, i.e., from 160 to 100 mg/dL. When the fasting plasma glucose declines toward normoglycemic levels, activation of the renal sympathetic nerves stimulates the liver to undergo glucogenesis and glycogenolysis, and quantitatively this increases hepatic glucose production (HGP), matching the glucose amount excreted in the urine, thus preventing hypoglycemia. The decline in plasma glucose concentration creates a state of tissue energy deprivation and leads to a decrease in plasma insulin and an increase in plasma glucagon concentration. These resultant hormonal changes stimulate lipolysis, thus providing substrate for ketogenesis, and reset the liver into the ketogenic mode. Subsequent ketone (β-hydroxybutyrate [β-OH-B]) production provides a fuel-efficient substrate for the heart and the kidney. In muscle, glycogen breakdown is stimulated, providing the carbon skeleton for the synthesis of alanine (Ala), which is released into the circulation and transported to the liver to support gluconeogenesis (known as the alanine cycle). Stimulation of muscle proteolysis also results in the release of alanine as well as other amino acids, in particular the branched-chain amino acids (BCAAs): leucine (Leu); isoleucine (Isoleu); and valine (Val). The liver does not possess BCAA transferase, allowing the BCAAs to be taken up by the heart and kidney where they provide substrate to compensate for the reduction in plasma glucose concentration that occurs secondary to the glucosuric effect of the SGLT2i. PYR, pyruvate.

SGLT2-Inhibitoren: Glukosurie als Erklärung für kardiorenale Schutzwirkung?

Natrium-Glukose-Cotransporter-2-Inhibitoren senken Risiko für Nephrolithiasis

Typ-1-Diabetes: SGLT2-Hemmung optimiert renalen Energiestoffwechsel

Schwere Ketoazidose nach SGLT2-Hemmer-Einnahme bei 2 Patienten ohne Diabetes

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors

Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE

A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease

Efficacy and safety of SGLT2 inhibitors in nondiabetic patients with CKD: a review of recent evidence

State-of-the-art-review Mechanisms of action of SGLT2 inhibitors and clinical implications

BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes

Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes

Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench

SGLT2 Inhibition: A New Glimmer of Hope to Slow Chronic Kidney Disease Progression in Children?

SGLT2 inhibitors: cardiorenal metabolic drugs for the ages

Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease

How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial

SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action

SGLT2 inhibitors and kidney outcomes across the spectrum of kidney disease: a systematic review and meta-analysis

The Rationale and Evidence for SGLT2 Inhibitors as a Treatment for Nondiabetic Glomerular Disease

Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk